UNSPSC 51172502: Atropine/pralidoxime

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AD900. This VA Drug Class (AD900) classifies this compound as belonging to the group ANTIDOTES/DETERRENTS, OTHER.

UNSPSC 51172502 Atropine/pralidoxime, a Commodity code, nominally encompasses pharmaceutical antidotes and nerve-agent countermeasures, but recent state and local procurement activity under this code shows minimal relevant solicitation volume. The single recent opportunity posted under the code — Seminole County, Florida's IFB60459723LAS — targets naloxone and drug deactivation systems for community health support, a scope unrelated to atropine or pralidoxime procurement. The code does not reflect active state and local buying for the pharmaceutical antidotes its name describes.

Seminole County's naloxone procurement (IFB60459723LAS, posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The contract carried a two-year initial term with an optional one-year renewal, fixed-fee pricing, E-Verify and drug-free workplace compliance requirements, and potential FEMA funding with associated federal environmental-compliance obligations. Beyond this single opportunity, the code shows no other recent state and local activity under its intended commodity scope.